Opaganib

Drug identity checked against registry records

Also recorded as ABC294640; Yeliva

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 PneumoniaNCT04467840RedHill Biopharma LimitedPhase 2, Phase 3Completed2021-07-18Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.